Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions.

Allergology international : official journal of the Japanese Society of Allergology - 1 Oct 2024

Hsu Hung-Chih, Chung Wen-Hung, Lin Yung-Chang, Yang Tsai-Sheng, Chang John Wen-Cheng, Hsieh Chia-Hsun, Hung Shuen-Iu, Lu Chun-Wei, Chen Jen-Shi, Chou Wen-Chi, Wang Chuang-Wei

Abstract excerpt

BACKGROUND: Oxaliplatin is commonly used to treat gastrointestinal malignancies. However, its applications are limited due to potential adverse drug reactions (ADRs), particularly severe anaphylactic shock. There is no method to predict or prevent ADRs caused by oxaliplatin. Therefore, we aimed to investigate the genetic HLA predisposition and immune mechanism of oxaliplatin-induced ADRs. METHODS: A retrospective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Anaphylaxis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Drug Hypersensitivity

Share to Drug-Related Side Effects and Adverse Reactions

Share to HLA Antigens

Share to Immunoglobulin E

Share to Oxaliplatin

Source

Identifiers

PMID: 38594174
DOI: 10.1016/j.alit.2024.03.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions.PMID 38594174Read ↗

Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: phenotypes, endotypes and management with desensitization.Semantic proximity Read ↗

Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: Phenotypes, endotypes, and management with desensitization.Semantic proximity Read ↗

Updates on Oxaliplatin-Induced Peripheral Neurotoxicity (OXAIPN)Semantic proximity Read ↗

Distinct Adverse Event Profiles of Eight Chemotherapeutic Agents: A FAERS Database Analysis Focusing on Peripheral NeuropathySemantic proximity Read ↗

Association between germ-line HLA and immune-related adverse eventsSemantic proximity Read ↗

Exome array analysis of adverse reactions to fluoropyrimidine-based therapy for gastrointestinal cancer.Semantic proximity Read ↗

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.Semantic proximity Read ↗

Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapy.Semantic proximity Read ↗

Electrolyte disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseSemantic proximity Read ↗

From acute phase mediators to drug provocation testing: a single center experience in the allergy work-up of adverse drug reactions to chemotherapySemantic proximity Read ↗

HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.Semantic proximity Read ↗

HLA-DR9 and DR14 are associated with the allopurinol-induced hypersensitivity in hematologic malignancy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.